"Bhagwan Mahaveer Cancer Hospital and Research Centre, Jaipur (BMCHRC), a NABH accredited institution, was established in the year 1997 as a cancer speciality hospital offering cancer prevention, treatment, education and research centre. Started with just 50 beds at the initial stage, it grew into a super-speciality, 300-bedded hospital with leading-edge infrastructure housing several wards, laboratories, utility services and specialities after 24 years. Today, BMCHRC has its own Surgical Oncology, Medical Oncology, Radiation Oncology, Radiology, Nuclear Medicine, Pathology departments, and a huge Blood Bank. From a 50 bedded facility to a 300 bedded super speciality hospital, BMCHRC has come a long way in patient care."

During the past decade, Bhagwan Mahaveer Cancer Hospital & Research Centre conducted 10 clinical trials. In the 10-year time frame, 10 clinical trials started and 4 clinical trials were completed, i.e. on average, 40% percent of trials that started reached the finish line to date. In the past 5 years, 6 clinical trials started and 2 clinical trials were completed. i.e. 33.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Bhagwan Mahaveer Cancer Hospital & Research Centre" #1 sponsor was "Janssen Research & Development, LLC" with 4 trials, followed by "Merck KGaA, Darmstadt, Germany" with 3 trials sponsored, "Johnson & Johnson Private Limited" with 2 trials sponsored, "Bayer" with 1 trials sponsored and "CTI BioPharma" with 1 trials sponsored. Other sponsors include 1 different institutions and companies that sponsored additional 11 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Bhagwan Mahaveer Cancer Hospital & Research Centre" #1 collaborator was "Merck Ltd., India" with 3 trials as a collaborator, "Eisai Europe Ltd. (United Kingdom)" with 1 trials as a collaborator, "Pharmacyclics LLC." with 1 trials as a collaborator, "THINQ Pharma CRO Ltd." with 1 trials as a collaborator and "Unique Pharmaceuticals Ltd, India" with 1 trials as a collaborator. Other collaborators include -5 different institutions and companies that were collaborators in the rest 5 trials.

According to Clinical.Site data, the most researched conditions in "Bhagwan Mahaveer Cancer Hospital & Research Centre" are "Lymphoma, Mantle-Cell" (3 trials), "Leukemia, Lymphocytic, Chronic, B-Cell" (2 trials), "Breastcancer" (1 trials), "Carcinoid Syndrome" (1 trials) and "Carcinoma, Squamous Cell" (1 trials). Many other conditions were trialed in "Bhagwan Mahaveer Cancer Hospital & Research Centre" in a lesser frequency.

Most popular intervention types in "Bhagwan Mahaveer Cancer Hospital & Research Centre" are "Drug" (15 trials), "Biological" (1 trials) and "Radiation" (1 trials). Other intervention types were less common.

The name of intervention was led by "Bortezomib" (2 trials), "Cetuximab" (2 trials), "Dexamethasone" (2 trials), "Ibrutinib" (2 trials) and "Lenalidomide" (2 trials). Other intervention names were less common.

The vast majority of trials in "Bhagwan Mahaveer Cancer Hospital & Research Centre" are 13 trials for "All" genders, 2 trials for "Female" genders and 2 trials for "Male" genders.

Currently, there are NaN active trials in "Bhagwan Mahaveer Cancer Hospital & Research Centre". undefined are not yet recruiting, 6 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 5 completed trials in Bhagwan Mahaveer Cancer Hospital & Research Centre, undefined suspended trials, and 4 terminated clinical trials to date.

Out of the total trials that were conducted in Bhagwan Mahaveer Cancer Hospital & Research Centre, 1 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 9 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 1 trials that are defined as “Not Applicable".